🇺🇸 FDA
Pipeline program

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

16995

Approved small_molecule completed

Quick answer

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) for Neovascular Macular Degeneration is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Neovascular Macular Degeneration
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials